A. Gazzah

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

Geoffrey R. Oxnard, Vivek Subbiah, K. Park et al. · Journal of Thoracic Oncology · 2018 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

Antoine Hollebecque, Éric Deutsch, C. Massard et al. · Investigational New Drugs · 2013 · 26 citations

Medicine, Oncology, Pharmacology +10

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Myriam Kossaï, Boris Duchemann, C. Boutros et al. · Lung Cancer · 2015 · 15 citations

Medicine, Oncology, Pharmacology +11

Long term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation

M-L. Gauci, Émilie Lanoy, Stéphane Champiat et al. · Annals of Oncology · 2017 · 12 citations · Full text

Pharmacy, Immunology, Oncology +14

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study

Laura Mezquita, Fabrice Barlési, Édouard Auclin et al. · Journal of Thoracic Oncology · 2018 · 12 citations · Full text

Medicine, Molecular Medicine, Oncology +15